LEE011

Phase 1Completed

0 views this week 0 watching💤 Quiet

Interest: 29/100

Hype Score

Development Stage

✓

Pre-clinical

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Normal Hepatic Function

Conditions

Normal Hepatic Function, Impaired Hepatic Function

Trial Timeline

Mar 25, 2015 → Jan 9, 2017

NCT ID

NCT02388620

About LEE011

LEE011 is a phase 1 stage product being developed by Novartis for Normal Hepatic Function. The current trial status is completed. This product is registered under clinical trial identifier NCT02388620. Target conditions include Normal Hepatic Function, Impaired Hepatic Function.

What happened to similar drugs?

4 of 6 similar drugs in Normal Hepatic Function were approved

Approved (4) Terminated (2) Active (2)

✅DonepezilEisaiApproved

✅Eybelis ophthalmic solution 0.002%Santen PharmaceuticalApproved

✅cyclosporine micro-emulsionNovartisApproved

✅Aspirin 100 mg + PlaceboBayerApproved

🔄Gadopentetate dimeglumine (Magnevist)BayerPhase 3

🔄lixivaptan + placeboBiogenPhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (8)

NCT ID	Phase	Status	Start	Completion	Indication
NCT02934568	Phase 2	Active	Dec 15, 2016	Feb 1, 2027	Continued Access to Study Treatment(s), Cancers With a Mass, Bulky Tumor, Nodule, Lump, Advanced Cancer, Advanced Solid Tumors, Advanced Solid Malignancies
NCT02524119	Phase 2	Terminated	Apr 1, 2016	Sep 1, 2020	Hepatocellular Carcinoma
NCT02431481	Phase 1	Completed	Oct 23, 2015	May 11, 2018	Normal Renal Function
NCT02388620	Phase 1	Completed	Mar 25, 2015	Jan 9, 2017	Normal Hepatic Function
NCT02187783	Phase 2	Completed	Aug 25, 2014	Jan 17, 2018	Tumors With CDK4/6 Pathway Activation
NCT01747876	Phase 1	Terminated	May 28, 2013	Jun 29, 2017	Malignant Rhabdoid Tumors (MRT)
NCT01898845	Phase 1	Completed	May 1, 2013	Jan 1, 2015	Advanced Solid Tumors
NCT01237236	Phase 1	Completed	Dec 21, 2010	Mar 9, 2017	Advanced Solid Tumor

Competing Products

20 competing products in Normal Hepatic Function

See all competitors

Product	Company	Stage	Hype Score
Roxadustat	Astellas Pharma	Phase 1	29
Donepezil	Eisai	Approved	43
eribulin mesylate	Eisai	Phase 2	35
Lurasidone HCl	Sumitomo Pharma	Phase 1	29
Eybelis ophthalmic solution 0.002%	Santen Pharmaceutical	Approved	39
Triptorelin	Merck	Pre-clinical	26
Temozolomide + Vorinostat	Merck	Phase 2	35
LDE225	Novartis	Phase 1	29
LDK378	Novartis	Phase 1	29
cyclosporine micro-emulsion	Novartis	Approved	35
LDK378	Novartis	Phase 1	29
LEE011	Novartis	Phase 1	29
mycophenolate mofetil	Roche	Phase 1	29
filgrastim	Amgen	Pre-clinical	26
PF-06423264	Pfizer	Phase 1	21
PF-05221304	Pfizer	Phase 1	29
BMS-933043 + Placebo matching with BMS-933043 + Antacid Buffer Predose Solution	Bristol Myers Squibb	Phase 1	29
tolebrutinib	Sanofi	Phase 1	29
Venglustat (GZ402671)	Sanofi	Phase 1	29
Rilzabrutinib	Sanofi	Phase 1	29